Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.44 |
| ▸ | MET | P08581 | 7/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14191531 | 0.87 | GPR119 (0.51) | ROCK2 | |
| SCHEMBL4049899 | 0.84 | SPHK2 (0.44) | SPHK2ROCK2SPHK1METCNR2 | |
| SCHEMBL4048867 | 0.84 | SPHK2 (0.44) | SPHK2ROCK2SPHK1METCNR2 | |
| SCHEMBL16803919 | 0.83 | ROCK2 (0.43) | SPHK2ROCK2SPHK1METCNR2 | |
| SCHEMBL15537658 | 0.81 | SPHK2 (0.42) | SPHK2ROCK2SPHK1METCNR2 | |
| SCHEMBL15540246 | 0.81 | SPHK2 (0.42) | SPHK2ROCK2SPHK1METCNR2 | |
| SCHEMBL4456659 | 0.80 | PARP15 (0.48) | MAP4K4 | |
| SCHEMBL4457549 | 0.80 | HRH3 (0.47) | POLB | |
| SCHEMBL4457038 | 0.80 | POLB (0.51) | POLB | |
| SCHEMBL4461701 | 0.80 | HDAC4 (0.44) | VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059517-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | Biovitrum AB (publ) (SE) | 2009-05-20 | — | — | EP | claimed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| WO-2008025800-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | claimed |
| EP-2059517-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | Biovitrum AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025800-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103141-A1 | New compounds | GPR119, GPR3, GPR4 | SPHK2 3643/4885ROCK2 2736/4885SPHK1 3955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.